July 26, 2022 03:58 PM Eastern Daylight Time
YOKNEAM, Israel & TORONTO–(BUSINESS WIRE)–Rapid Medical, a leading developer of advanced neurovascular devices, announces FDA 510(k) clearance for TIGERTRIEVER™13 for large vessel occlusions at the 2022 Society of NeuroInterventional Surgery’s (SNIS) 19th Annual Meeting in Toronto. TIGERTRIEVER 13 is the smallest revascularization device in the world to date and is designed to remove thrombus from delicate brain blood vessels during an ischemic stroke. It is the only device that adjusts to the vasculature and clot, a more atraumatic approach than existing devices.
“The neurovascular field has been waiting for a thrombectomy device dedicated to small vessels,” states Dr. David Fiorella of Stony Brook University Medical Center in Stony Brook, NY. “Medical therapy is currently suboptimal for these patients, so there can be a huge benefit for devices that emergently restore blood flow while minimizing the potential for harm.”
Existing stent retrievers lack any adjustability– they open passively and are pulled from the brain fully expanded. The unique adjustability of the TIGERTRIEVER portfolio comes from complex three-dimensional braiding borrowed from recent advances in aerospace engineering. TIGERTRIEVER is precisely controlled to capture the thrombus and remove the tension from the vasculature before removal. Adjustability also gives TIGERTRIEVER 13 the lowest profile of any stent retriever—24% smaller than 3 mm devices, providing easier navigation in challenging anatomies. The ability to tailor each procedure can provide new safety levels for higher-risk thrombectomies.
“Thousands of procedures have already been performed with TIGERTRIEVER 13 worldwide,” describes James Romero, President, Americas, of Rapid Medical. “Now U.S. physicians finally have access to TIGERTRIEVER 13’s unique capabilities to further benefit patients suffering from ischemic stroke.”
About Rapid Medical
Rapid Medical develops the premier, responsive interventional devices for neurovascular diseases such as ischemic and hemorrhagic stroke. Utilizing novel manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the intravascular environment and have greater control over procedural outcomes. TIGERTRIEVER™17 and 21, COMANECI™, and COLUMBUS™/DRIVEWIRE are CE marked and FDA cleared. TIGERTRIEVER™13 and XL are also CE marked. More information is available at www.rapid-medical.com.
Contacts
Ronen Eckhouse
+972-72-2503331
ronen@rapid-medical.com
Together since 2007
Transforming money management to make financial markets accessible to all
Acquired since 2021
Enabling the human right of mobility to all
Acquired since 2017
Introducing Zero Trust mechanisms for a truly sale environment
Acquired since 1994
Introduced cyber security to the mass business market
Together since 2010
Harnessing the power of artificial vision to transform the lives of visually impaired
Together since 2020
Digital Learning Platform designed to optimize student engagement and learning outcome
Together since 2019
AI-driven end-to-end Fix & Flip platform
Together since 2021
First drone delivery service focused in the US suburbs.
Acquired by DG 2007
Global provider of digital advertising solutions that optimize the use of media, creative and data for enhanced performance.
Together since 2010
Leading investment house in Israel, managing over 77 Billion Dollars for private, business and institutional clients
Together since 2016
Developing and commercializing novel endovascular treatments for stroke
Together since 2012
Developing percutaneous implantable technologies for patients with chronic heart failure